Literature DB >> 9685243

A new approach to the design of novel inhibitors of Na+,K+-ATPase: 17alpha-substituted seco-D 5beta-androstane as cassaine analogues.

S De Munari1, P Barassi, A Cerri, G Fedrizzi, M Gobbini, M Mabilia, P Melloni.   

Abstract

A new three-dimensional model for the relative binding mode of cassaine 1 and digitoxigenin 2 at the digitalis receptor site is proposed on the basis of the structural and conformational similarities among 1, 2 and its 14,15-seco analogues 3 and 4. Accordingly, the speculation that also 17alpha-substituted derivatives of the digitalis 5beta,14beta-androstane skeleton could efficiently bind to the Na+,K+-ATPase receptor is put forward and verified through the synthesis of some related compounds. The binding affinity shown by 2-(N,N-dimethylamino)ethyl 3beta, 14-dihydroxy-5beta,14beta-androstane-17alpha-acrylate 6 (IC50 = 5.89 microM) and, much more significantly, by the corresponding 14, 15-seco-14-oxo derivative 9 (IC50 = 0.12 microM) substantiates the new hypothesis and opens new prospects to the design of novel inhibitors of Na+,K+-ATPase as potential positive inotropic compounds.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685243     DOI: 10.1021/jm980108d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Erythrofordins D and E, two new cassaine-type diterpenes from Erythrophleum suaveolens.

Authors:  Tanja Grkovic; Jason R Evans; Rhone K Akee; Liang Guo; Myrtle Davis; Johnson Jato; Paul G Grothaus; Michelle Ahalt-Gottholm; Melinda Hollingshead; Jerry M Collins; David J Newman; Barry R O'Keefe
Journal:  Bioorg Med Chem Lett       Date:  2018-12-10       Impact factor: 2.823

2.  Enhancing the potency of lithospermate B for inhibiting Na+/K+-ATPase activity by forming transition metal ion complexes.

Authors:  Nan-Hei Lin; Tse-Yu Chung; Feng-Yin Li; Hsin-An Chen; Jason T C Tzen
Journal:  Acta Pharmacol Sin       Date:  2013-05-20       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.